Evidence map›Paper›PMID 28584139›Full record

ArticleAntimicrobial agents and chemotherapy2017

Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-

Hajime Kanamori, Christian M Parobek, Jonathan J Juliano, James R Johnson, Brian D Johnston, Timothy J Johnson, David J Weber, William A Rutala, Deverick J Anderson

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  5. Genomic Characterization of Selected Multidrug-ResistantAnimals : an open access journal from MDPI · 2026
    Article
  6. Article
  7. A First Report on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. Evolution of extended-spectrum β-lactamase-producing ST131bioRxiv : the preprint server for biology · 2023
    Article
  11. Article
  12. Article
  13. Evaluation ofJAC-antimicrobial resistance · 2022
    Article
  14. Review
  15. Article
  16. Commensal Urinary Lactobacilli Inhibit Major UropathogensFrontiers in cellular and infection microbiology · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hajime KanamoriDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA kanamori@med.tohoku.ac.jp.
Christian M ParobekCurriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Jonathan J JulianoDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
James R JohnsonDivision of Infectious Diseases, University of Minnesota, Minneapolis, Minnesota, USA.
Brian D JohnstonDivision of Infectious Diseases, University of Minnesota, Minneapolis, Minnesota, USA.
Timothy J JohnsonDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, USA.
David J WeberDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
William A RutalaDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Deverick J AndersonDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.

Funding

Clinical and Molecular Epidemiology of Multidrug-Resistant Organisms in a CommuniK23AI095357 · NIAID · DUKE UNIVERSITY · PI ANDERSON, DEVERICK JOHN · 2011 to 2015
$644k
Investigating the targets and strain specificity of antibodies against P. vivaxF30AI109979 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAROBEK, CHRISTIAN · 2015 to 2017
$108k
Gut reservoir of E. coli ST131I01CX000920 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI JOHNSON, JAMES R · 2014 to 2021
–
CSRD VA I01 CX000920NIAID NIH HHS F30 AI109979NIAID NIH HHS K23 AI095357
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial Agentsbeta-LactamasesDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsFluoroquinolonesGenome, BacterialHospitals, CommunityHumansMolecular EpidemiologyMultilocus Sequence TypingNorth CarolinaPlasmidsTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial Agentsbeta-lactamase CTX-M, E colibeta-LactamasesEscherichia coli ProteinsFluoroquinolonesTrimethoprim, Sulfamethoxazole Drug Combinationcommunity hospitalsCTX-Mextended-spectrum β-lactamase (ESBL)multidrug-resistant (MDR) Escherichia coliwhole-genome sequencing

Identifiers

PMID28584139
PMCPMC5527606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.